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The DNA-binding  domain of the mouse uterine  estro- 
gen  receptor  (ER)  was  characterized  using  site-specific 
polyclonal antibodies. The peptides used as antigens 
have sequences corresponding  to  amino  acids 185-199 
and 227-245, the  two  zinc  finger  regions of the DNA- 
binding  domain of the  human  ER,  and  produced  anti- 
sera designated A- 1542  and A- 1554, respectively. 
Mouse uterine  nuclear ER and  salt-activated 4 S cyto- 
sol receptor, as well as 8 S untransformed cytosol 
receptor,  were  observed  to  react  with  the  antisera  by 
Western  blot and sucrose  density  gradient  centrifuga- 
tion  analyses  indicating  that  the DNA-binding  domain 
of the 8 S cytosol receptor is not  completely  masked by 
heat  shock  protein 90 or  other proteins.  Only  A-1554 
detected a nuclear-specific  doublet  form of the ER  on 
Western blot analysis. In a gel shift assay, neither 
antisera  altered  the  pattern of the  nuclear ER inter- 
action  with  the  vitellogenin A2 estrogen  response  ele- 
ment (VRE). In  contrast,  antiserum  A-1554  partially 
shifted the 8 S cytosol receptor-VRE complex. This 
concurs  with  mutational  analysis  and  x-ray  crystallog- 
raphy  studies  with  the  human ER that  have  shown  that 
the second finger is not in  contact  with  the DNA. The 
results of the gel  shift  assay  were  confirmed by  sucrose 
density  gradient  analysis  using  the  same  buffer condi- 
tions. The  nuclear  receptor-VRE complex  did  not react 
with  either  antisera,  suggesting  that  when  the  dimeric 
nuclear receptor form binds the VRE, the specific 
receptor  epitopes  involved  with the DNA binding  may 
be blocked and unable  to  bind  the  antisera.  The cytosol 
receptor-VRE  complex  reacted  only  partially  with  the 
second finger antisera A-1554, suggesting that on 
receptor monomers the second finger epitope is not 
completely  blocked by DNA binding or dimer  forma- 
tion. 
Steroid  hormone  receptors  are a class of ligand-inducible, 
trans-acting regulatory factors  that  activate gene transcrip- 
tion by binding  as  dimers  to specific DNA sequences termed 
hormone-responsive  elements (1). The receptor  proteins  for 
steroids,  thyroid  hormone,  vitamin  D,  and  retinoids comprise 
a  group of proteins which are  members of a superfamily of 
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molecular transcription factors (2, 3). Structural analysis 
indicates  steroid  hormone  receptors  are composed of six  major 
functional  domains (4, 5 ) .  Domains A/B in  the  NHn-terminal 
region of the  protein comprise  a hypervariable region contain- 
ing transactivation domains. Domain C, the DNA-binding 
domain  contains a 66-68 amino acid region arranged  in two 
zinc-stabilized DNA-binding finger  motifs, CI  and CII. Mu- 
tational  analysis  has  shown  that  the  CI finger determines  the 
specificity of DNA  binding by making  contacts  with  bases  in 
the  hormone-responsive  elements  (6).  Three  amino acid 
changes at  the  COOH-terminal  base of the  CI finger allows 
ER’  recognition of glucocorticoid  responsive element se- 
quences (7). DNA-bound  receptors  are believed to be stabi- 
lized by contacts  with  the  DNA  phosphate backbone contrib- 
uted by CII (8). Region D contains sequences that  function 
as a nuclear localization signal. Ligand-binding  and ligand- 
dependent  transcriptional  activation  domains  are located in 
domain E. 
The  non-transformed  state of steroid  receptors observed in 
the  absence of hormone  binding  is  thought  to  be composed of 
a multicomponent protein complex. Most notably, the 90- 
kDa  heat  shock  protein (hsp9O) which constitutes 0.1-2%  of 
cell protein  is  reported  to  associate  with  steroid  receptors (9, 
10).  Proposals were made suggesting that  the  binding of hsp90 
masks the DNA-binding domain ( l l ) ,  thereby preventing 
DNA binding. Upon  hormone  binding, hsp90 is released al- 
lowing receptor  interaction  with  DNA  (12). However, recent 
studies  with  native  ER suggest that  in  the  absence of hormone 
and  under low salt  conditions where  hsp90 would be expected 
to  be  bound,  the  receptor  can  bind specific DNA  containing 
hormone-responsive  elements in vitro (13). 
Recent reports of NMR (14) and x-ray crystallographic 
analyses  (15) of the glucocorticoid receptor  and  NMR  analysis 
of the  ER DNA-binding  domain (8) have  shown that  the two 
DNA-binding  domain  fingers  are  positioned at  a right  angular 
orientation. It is indicated that other regions (TAF-1 and 
TAF-2) of the  protein influence transcriptional  activity of the 
receptor (16,  17) and probably its  conformation for interacting 
with DNA (18). Since NMR and crystallographic studies 
utilized primarily  the  DNA-binding  domain,  it  remains  to be
established  what influence other  domains of the  full-length 
receptor  have  on  the  DNA  interaction.  To  further  investigate 
the specific structure  and  interaction of native mouse uterine 
ER with DNA,  polyclonal antibodies were raised against two 
specific peptide sequences from  the  CI  and  CII regions  in the 
DNA  binding region. The  antisera were used to  characterize 
The abbreviations used are: ER, estrogen receptor;  ERE, estro- 
gen-responsive element;  VRE,  vitellogenin A2 estrogen response ele- 
ment; PBS, phosphate-buffered saline; hsp90, heat shock protein 90. 
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FIG. 1. The DNA-binding  domain 
of the estrogen receptor. The  amino 
acid sequence of the DNA-binding do- 
main  is indicated  above and  its zinc fin- 
ger structure  is  hown schematically. 
Underlined portions of the  sequence  in- 
dicate  peptides (264 and 267) that were 
synthesized and used to generate anti- 
sera A-1542 and A-1554 respectively. (+) 
marks  indicate  charged  amino acids. (*) 
indicates conserved cysteine residues. 
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the  structure  and  binding  interaction of the DNA domain of 
different  forms of the  native mouse ER. 
EXPERIMENTAL  PROCEDURES 
Materia/~-17~-[2,4,6,7-~H]Estradiol (94.7 Ci/mmol) was pur- 
chased from Du  Pont-New  England Nuclear. Electrophoretic  reagents 
were obtained  from  Bio-Rad.  Ultra  pure  sucrose  was  obtained  from 
Bethesda Research Laboratories.  Estrogen  receptor  antibody  (H222) 
was  a  generous  gift  from  Dr. Chris  Nolan,  (Abbott  Laboratories). 
Buffers-The following buffers were used TE buffer  (10 mM Tris, 
1.5 mM EDTA,  pH 7.4). TEK buffer (TE buffer plus 0.4 M KCI), and 
TEGM buffer (10 mM Tris, 1.5 mM EDTA, 10% (v/v) glycerol, 3 mM 
MgC12). Additional buffers  contained 3 mM EGTA,  50 pg/ml each of 
leupeptin,  antipain,  chymostatin,  and  soybean  trypsin  inhibitor  and 
were  designated as  TEPI,  TEKPI  and  TEGMPI buffers,  respectively. 
Buffers which contained  10 mM sodium molybdate were designated 
as  TEPIMo  and  TGMMo buffers. TAE buffer contained 6.7 mM Tris, 
3.3 mM sodium acetate, 1 mM EDTA, pH 7.5. 
Animal  and Tissue Preparation-Animal studies were conducted 
under  an  approved  National  Institutes of Health protocol in accord 
with  the  principles  and  procedures of the  NIH  Guide for the  Care 
and Use of Laboratory Animals. Female CD-1 mice were obtained 
from Charles River (Raleigh, NC). Bilateral ovariectomy was per- 
formed on  animals at 10 weeks of age. Animals were sacrificed by 
cervical dislocation 2 weeks after ovariectomy. The uteri were re- 
moved and  immediately frozen on  dry ice and  stored  at -70 C until 
use. 
Preparation of the Cytosol Receptor and  the  Ammonium  Sulfate- 
fractionated Cytosol-The cytosol receptor  fraction was prepared  from 
ovex mouse uteri by homogenization with TEPI  or  TEKPI buffers 
(19). The homogenate  was centrifuged a t  105,000 X g for 50  min  to 
obtain  the cytosol. For  some  studies,  ammonium  sulfate was added 
to  the cytosol a t  40% saturation as previously described (20). The 
resulting  precipitate  was collected by centrifugation at 8,800 X g for 
30 min, resuspended, and dialyzed against  TGM. 
Preparation of Nuclear Receptor-The nuclear receptor fraction 
was prepared following treatment of ovex mice with  either  unlabeled 
estradiol  or  tritiated  estradiol as described  previously (13). The  uteri 
were homogenized with TEGMPI buffer  and  filtered  through  Nytex 
(100-125 pm).  The  filtrate  was  centrifuged a t  2,500 X g for 10 min. 
The pellet was washed  twice with homogenization  buffer and resus- 
pended in buffer containing 0.4 M KC1 and allowed to  extract for 30 
min. The  suspension was centrifuged at 105,000 X g for 50 min. For 
Western blots, ER was extracted  from  the  nuclear  pellet  in 5% SDS 
and  prepared  as previously  described (21). 
Partially Purified Estrogen Receptor-Partially purified E R  was 
prepared from ovex mouse uteri  using  estrogen  affinity  column  chro- 
matography (20). 
Preparation and Purification of the Antisera-The synthesis of 
peptides 264 and 267 and preparation of the immune sera were 
reported previously  (22,  23). Antiserum A-1542 or A-1554 were used 
as crude sera or after purification on an antigen-linked Sepharose 
affinity column (22) or protein A-Sepharose affinity column. The 
immune sera were assaved bv enzvme-linked immunoassav with 
1st finger  2nd  finger 
FIG. 2. Antisera   A-1542 and A-1554 detection of estrogen 
receptor on Western blots. Partially purified cytosol ER  (20 ng) 
was  electrophoresed on SDS-polyacrylamide gel electrophoresis and 
transferred by diffusion blotting to nitrocellulose strips.  The  strips 
were probed with H222 (lane 1 ), control preimmune rabbit serum 
(lanes 2 and 5), antiserum A-1542 (lane 3 ) ,  antiserum A-1554 (lane 
6), affinity purified antiserum A-1542 (lane 4 ) ,  or affinity purified 
A1554 (lane 7). The molecular  weights of the full-length ER (65,000) 
and a major  proteolytic  fragment (54,000) are indicated. 
nitrocellulose sheet by diffusion blotting  (20)  and reacted  overnight 
with the rabbit anti-ER peptide antiserum a t  room temperature. 
Nitrocellulose strips were washed and incubated with '2sII-labeled 
secondary  antibody  (rabbit) as described  previously (20). 
Sucrose Density  Gradient Analysis-Sucrose density  gradients (5- 
20% or 5-30% w/v) were formed and collected with a Haake Buchler 
Auto Densi-Flow. Gradients were made in TE, TEK,  or  TAE buffers 
as indicated.  Gradients were centrifuged for 17 h a t  180,000 X g in a 
Beckman  SW60 Ti  rotor,  and  three  drop  fractions were collected for 
analysis of radioactivity profile. 
Protein Concentration  Determination-Protein concentrations 
were determined by the  Bradford  method  using  rabbit y-globulin as 
the  protein  standard (24). 
DNA Binding Assays-Receptor binding  to DNA was assayed  using 
sucrose density gradient centrifugation or gel shift assays. The gel 
shift  assay was  performed as described previously (13). A  32P-labeled 
56-base  pair  synthetic  DNA  fragment  containing  the vitellogenin A2 
ERE (20-40 fmol) was incubated with ammonium  sulfate  fractionated 
ER (3.2-4 pg of protein; 3.1 fmol of receptor) with or  without 10 nM 
estradiol  or  nuclear  extract (12.5 pg of protein; 30 fmol of receptor). 
In  some  experiments  receptor  preparations were incubated for 20 h 
a t  0 "C with 6 pl of PBS  and  an aliquot of protein A-Sepharose- 
purified A-1542, A-1554 antiserum  or monoclonal antibody H222 as 
listed  in  the figure legends. For sucrose density  gradient centrifuga- 
tion,  the  incubation volume was  increased  with buffer used for the 
gel shift  assay  to provide  sufficient  sample.  Nuclear  receptor  reaction 
mixtures were diluted  with  an equal  volume of TAE  alone  or cytosol 
receptor was preincubated with  a DCC (5%  charcoal, 0.5% dextran) 
TAE solution to absorb free steroid before application  to  the gradient. 
RESULTS 
detection a t  greater  than-10,000-folddilution. Western Blot Analysis of ER-Fig. 1 shows a schematic 
was carried  out  as previously  described (20)  with a 9-15% exponential diagram Of the conserved region Of the DNA-binding 
acrylamide gradient gel or a standard 8% gel with 3% acrylamide domain of the ER with the sequence  highlighted for Peptides 
stacking gel. After electrophoresis, the protein was transferred to 264 and 267 used in antibody production. Reactivity of the 
Western Blot Analysis-SDS-polyacrylamide gel electrophoresis 
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FIG. 3. Western blot analysis  of  the ER using  affinity puri- 
fied antiserum. Sample preparation and electrophoretic protein 
separation were performed as outlined in the legend to Fig. 2 and 
under  “Experimental Procedures.” Partially purified  cytosol ER (20 
ng) was probed with preimmune serum (lane I), antiserum A1542 
(lane 2 ) ,  antiserum A1542 preincubated with peptide 264 (lane 3 ) ,  
affinity purified antiserum A1554 (lane 4 ) ,  affinity purified antiserum 
A1554 preincubated with peptide 267 (lane 5 ) ,  or H222 (lane 6). 




A B C D E  
P 
10 20 




FIG. 4. Western blot analysis of the nuclear ER. A 500-pg 
sample of nuclear  protein  containing ER was  applied to each  lane, 
electrophoresed, and  transferred  to nitrocellulose strips as described 
in the Fig. 2 legend. The strips were probed with H222 (lane A ) ,  
preimmune serum (lanes C and E ) ,  antiserum A-1554 (lane R ) ,  or 
antiserum A-1542 (lane D). 
two rabbit  antisera, A-1542 and A-1554, with  partially purified 
mouse uterine ER was shown by Western  blot  analysis. Be- 
cause A-1542 and A-1554 produced a high background on 
Western blots, they were purified with a peptide-linked  Seph- 
arose affinity column. The reactivity of preimmune sera, 
antisera,  and purified antisera  toward  partially purified cyto- 
sol ER is shown in Fig. 2. In agreement with our previous 
results, multiple bands were observed which resulted from 
proteolysis of the  native 65,000 ER  to a truncated 54,000 form 
(19). The 65,000 full-length receptor and 54,000 fragment 
form reacted  with antisera A-1542 and A-1554 (lanes 3 and 
6) ,  and affinity purified A-1554 (lane 7), but not affinity 
purified A-1542 (lane 4 ) .  Antibody A-1554 showed similar 
reactivity  after  purification,  but  exhibited a lower background. 
A-1542 showed stronger  reactivity  than A-1554 at  the  same 
200-fold dilution. Samples  in Fig. 2, lane I ,  were probed  with 
H-222, a monoclonal anti-ER antibody (20), as a positive 
control. Monoclonal H-222 showed the 65,000 and 54,000 
bands,  but  not  the nonspecific lower molecular weight band 
seen with the  serum-probed  samples (lanes 2-7). Specificity 
of the  crude A-1542 and purified A-1554 was tested by prein- 
cubating  each  antiserum  with  the  corresponding  peptide  an- 
tigen. The 65,000 and 54,000 immunoreactive  bands were not 
top Fraction Number 
bottom 
of the cytosol ER with A-1542 and A-1554 in high salt (0.4 
FIG. 5. Sucrose density gradient analysis of the reactivity 
M KCl) buffer. Mouse uterine cytosol was prepared in TEKPIMo, 
labeled  with 10 nM [‘Hlestradiol, and  incubated  at 0 “C for 20 h  with 
preimmune serum, A-1542 or A-1554 preincubated with PBS, or 
corresponding  peptides  in  PBS. After DCC treatment, samples were 
centrifuged  on 5-20s sucrose gradients  in TEK for 17 h at  180,000 
X g. [“C]Ovalbumin (3.6 S) and [“C].y-globulin (7 S) were used as 
internal  markers. A ,  ER incubated wlth preimmune serum (0); A- 
1542 (A); A-1542 and  peptide 264 (0). B, preimmune  serum (0); A- 
1554 (A); A-1554 and  peptide 265 (0). 
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FIG. 6. Sucrose density gradient analysis of the  reactivity 
of molybdate stabilized cytosol ER with A- 1542 or A- 1554 in 
low salt buffer. Mouse uterine  cytosol was prepared in TEPIMo, 
labeled with 10 nM [3H]estradiol and incubated at 0 “C for 20 h with 
PBS (0), protein A-Sepharose purified A-1542 (0) or A-1554 (A). 
After DCC treatment, samples were centrifuged on 5-20% sucrose 
density gradients in TE buffer for 17 h at 180,000 X g. [14C]Ovalbumin 
(OV) and [“Cly-globulin ($2) were used as internal markers. 
detected (Fig. 3, lanes 3 and 5 ) ,  although some nonspecific 
bands were detected  on  the nitrocellulose strips. 
Our earlier findings demonstrated that monoclonal anti- 
body H-222 or H-226  detected a closely spaced  nuclear ER 
doublet of 66.5 and  65  kDa  when  analyzed by SDS-polyacryl- 
amide gel electrophoresis (21). Analyses of uterine nuclear 
ER showed that  antisera A-1542 detected two  specific bands 
of the  receptor (Fig. 4, lane D )  the  same  as  H-222 (lane A ) .  
In  contrast, only one  receptor  band was  readily detected  with 
A-1554 (Fig. 4, lane B ) .  These findings were confirmed by 
densitometric  analyses  (data  not  presented).  The  sensitivity 
of antibody A-1554 was tested by using a  2-fold  higher con- 
centration; however, A-1554 was still unable to  detect the 
upper  band of the  nuclear  ER doublet. 
Reactivity of Different Molecular Forms of ER-The struc- 
ture of the  different  forms of the cytosol ER were analyzed 
with  the  DNA domain-specific antibodies by sucrose  gradient 
centrifugation under high salt (Fig. 5) or low salt (Fig. 6) 
conditions  in  the  presence of 10 mM sodium  molybdate. Under 
high salt  conditions (0.4 M KCl),  the  receptor  exists  as a  4 S 
monomer which shifts to 7-8 S after incubation with the 
antisera (Fig. 5). A-1542 shifts  the 4 S peak less efficiently 
(Fig. 5 A )  showing it  is less reactive than A-1554 (Fig. 5B). 
No  shifted  peaks were observed using  antisera  preincubated 
with  the  corresponding  cognate  peptides,  indicating  that  the 
antibodies were site-specific for their respective peptide se- 
quences. Increased concentrations of the antisera did not 
change  the  reactivity  (data  not  shown). 
In low salt  buffers  (no  KCl)  containing sodium molybdate, 
the cytosol receptor sediments a t  8 S on sucrose gradients 
(Fig. 6). Association of hsp90 and ER is stabilized in the 
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FIG. 7. Sucrose density gradient analysis of the reactivity 
of the nuclear ER with A- 1542 or A- 1554. The nuclear  receptor, 
prepared as described under “Experimental Procedures,” was incu- 
bated at 0 “C for 20 h with PBS (01, A-1542 (01, or A-1554 (A). 
Samples were centrifuged an 5 2 0 %  sucrose  density  gradients  in  TEK 
buffer for 17 h at 180,000 X g. [14C]Ovalbumin (OV) and [“Cly- 
globulin (yG) were used as internal markers. 
presence of molybdate ions. Incubation of molybdate stabi- 
lized ER, and purified antisera results in a 11 S receptor 
complex (Fig. 6). In low salt buffer, the 8 S receptor was 
shifted more  completely  by A-1542 than by A-1554 suggesting 
in  this  form  the  CI region may be more  exposed than  the  CII 
finger region. 
As shown in Fig. 7 ,  we observed specific reactivity and 
shifting of the 5 S nuclear  receptor  peak  with  both  antisera 
in a high salt (0.4 M KCl) gradient. Similar analysis of the 
nuclear  receptor  in low salt  gradients showed the  peaks were 
shifted more efficiently than in high salt buffer (data not 
shown).  This may indicate  the  receptor-antibody complex is 
more easily dissociated by the higher salt concentration in 
the buffers. 
Mobility Shift Analysis of ER-The structural form and 
accessibility of the  DNA-binding  domain of the receptor was 
further  investigated by analyzing  antibody reactivity in  the 
presence of a  specific DNA sequence. 32P-Labeled  VRE, which 
contains the estrogen-responsive element from the vitello- 
genin A2 gene,  was added to the cytosol or nuclear ER 
preparations before or after  antibody  addition  in  the  presence 
of large excess of poly(d1-dC). In the mobility shift assay, 
neither A-1542 or A-1554 reacted  with  the 5 S nuclear  receptor 
after  addition of the  VRE  (data  not  shown). A ternary com- 
plex  composed of the  nuclear  receptor,  the  antibody,  and  VRE 
was  observed only  with monoclonal antibody H-222. Neither 
DNA-binding  domain  antisera  appeared  to have an effect on 
binding of the  nuclear  receptor  to  VRE  using  this procedure. 
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Gel shift  assay profiles of the cytosol ER, which we have 
shown is able to bind VRE (13), are shown in Fig. 8. The 
cytosol receptor produced similar ”P-labeled VRE  bands  as 
the  nuclear receptors. The  band in Fig. 8,  lane 5, is specific, 
but  is  not  totally  eliminated  due  to  incomplete  competition 
+ 
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FIG. 8. Binding of antiserum 1554 to cytosol ER.VRE com- 
plex. The effect of protein  A-Sepharose-purified A-1542 or A-1554 
on  VRE  binding of the cytosol receptor ( E R c )  was examined  using 
the gel shift assay as described under “Experimental Procedures.” 
Lunes 1-5, ERc-”P-labeled VRE complexes were formed prior to 
addition of preimmune  serum (lane I), A-1542 (lane 2), A-1554 (lane 
3 ) ,  or H222 (lane 4 ) .  Lune 5 also  contains a  100-fold molar excess of 
unlabeled VRE. Star indicates specific ER-VRE  bands. Arrow indi- 
cates  antibody-shifted ER.  VRE complexes. 
A 
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which occurs from time  to  time in some sample  preparations. 
In  addition  to  the sp cific bands of the receptor-VRE complex, 
a small  amount of double-shifted complex was observed with 
A-1554 (arrow, Fig. 8, lane 3 ) .  Densitometric  scanning of the 
gel bands  indicated  approximately 10-15% of the  ER-VRE is 
supershifted with antiserum A-1554. No double shift was 
detected in the A-1542 sample. The double shift band was 
also observed  in preparations reacted  with H-222 (lane 4 ) .  
Sucrose Gradient Analysis in Presence of Specific DNA- 
Antibody-receptor-DNA  interactions,  binding of the  antisera 
to  the cytosol, and  nuclear  receptors were studied by sucrose 
gradient  analysis in the presence or  absence of VRE in the 
same  TAE buffer  used  in the gel shift assay  (Figs. 9 and  10). 
The 5 S nuclear  receptor-VRE  peak was shifted  to -8 S upon 
addition of VRE (Fig. 9C) .  The peak a t  8-9 S was further 
shifted by H-222  monoclonal antibody  indicating  the presence 
of the  ER (Fig. 9A) .  In  the  absence of VRE,  the 5 S nuclear 
receptor reacts with both antisera even in the presence of 
large excess of poly(d1-dC) to form a complex of 11 S (Fig. 
9B) .  In  contrast,  the 8-9 S ER-VRE  form  persisted when the 
nuclear receptor was reacted with either antisera before or 
after  addition of VRE  shown with A-1542 (Fig. 9C)  and A- 
1554 (data not presented) indicating these antisera do not 
bind  the  nuclear  ER when VRE is present.  The 8 S cytosol 
receptor  VRE complex can be shifted by H-222  monoclonal 
antibody (Fig. 1OA) but not by the DNA-binding domain 
antisera (Fig. 10R). The cytosol receptor in the absence of 
VRE can be shifted by both antisera suggesting that the 
antibody  binding is displaced by VRE binding. The gel shift 
showed  a small  amount of ER-VRE-antibody complex (Fig. 
8), which is not  detectable in the  gradient  assay,  and probably 
I I I 
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FIG. 9. Sucrose  density  gradient  analysis of binding of A-1542 or A-1554 to the  nuclear ER in  the  presence or absence of 
VRE. The nuclear  ER,  prepared as described under  “Experimental  Procedures,” was incubated with  poly(d1-dC) a t  0 “C for 20 min. Some 
samples were then  incubated with VRE a t  room temperature for 20 min before or  after  incubation a t  0 “C for 20 h with PBS,  protein A- 
Sepharose-purified A-1542 or A-1554, or H222. Samples were centrifuged on 5-30?; sucrose density gradients in TAE  buffer for 15 h at  
130,000 X g. [‘4C]Ovalbumin (OV) and [‘4C]y-globulin (-&) were used as  internal  markers. 5 S nuclear  ER was incubated with the following 
reagents  in  the  order listed. A: VRE + PBS (0); VRE + H222 (0). R: A-1542 (0); A-1554 (0). C VRE + A-1542 (0); A-1542 + VRE (0). 
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FIG. 10. Sucrose density gradient analysis of binding of A- 
1542 or A-1554 to the cytosol ER in the presence or absence 
of VRE under the buffer conditions used for the gel shift 
assays. The cytosol ER, prepared as described under  “Experimental 
Procedures,” was incubated with poly(d1-dC) at room temperature 
represents  residual  antibody  binding  that was not displaced 
at  the  concentration of VRE used. 
DISCUSSION 
Antisera raised against  peptides  corresponding in sequence 
to regions of the zinc  finger  motifs of the  ER  DNA-binding 
domain were found useful to probe the  structure of the  native 
mouse ER  bound  to  an  ERE. A similar  approach  to analyzing 
the  steroid  hormone  receptor  structure was reported by Traish 
et al. (25-27) for human  ER,  the  chicken  progesterone recep- 
tor by Smith et al. (22),  and  the  human glucocorticoid receptor 
by Wilson et al. (23)  and  Urda et al. (28), although  none of 
those  studies  evaluated  DNA-bound  receptor  structures. 
In cytosol preparations  from  unstimulated mouse uterus, 
the receptor is present as an 8-9 S form under low salt 
conditions  and 4 S in high salt (0.4 M KCl)  (29). The exact 
composition of the 8 S untransformed  ER complex is still  not 
clear. I t  is  reported  that  the  non-transformed h tero-oligomer 
(8-9 S) ER complex  includes two molecules of the  ER, two 
hsp90 proteins,  and possibly  a 59-kDa  protein  (p59)  (30).  It 
was  also  proposed that  when  bound, hsp90 masked  the  DNA- 
binding  domain,  thereby blocking the  ability of the  receptor 
to  bind  DNA  (12).  We show here  that epitope-specific anti- 
bodies A-1542 or A-1554 recognize the 8 S receptor on  West- 
ern blot and sucrose gradients in the presence of sodium 
molybdate, which stabilizes  the 8 S ER-  hsp90 complex. The  
reaction is inhibited by the specific VRE  DNA sequence, but 
not by nonspecific DNA poly(d1-dC). The  data suggest that 
the peptide antibodies raised against the DNA-binding do- 
main react specifically with the ERE-binding site on the 
receptor either in its heteromeric state presumably when 
hsp90 is  associated  with  the  ER  or  in  the  presence of onspe- 
cific DNA. However, receptor binding to a  specific ERE 
sequence precludes antibody interaction. Reactivity of the 
DNA  domain  antibodies  with low salt  molybdate-stabilized 8 
S ER suggests that  the zinc finger  regions of the  DNA-binding 
domain are not covered, but are accessible to the antisera. 
This is in  agreement  with  additional  studies showing the 8 S 
cytosol receptor  can  bind VRE (13,31,  32).  Dalman et al. (33) 
have used ER-retinoic acid receptor  chimeras  and  an  anti- 
hsp90 antibody to  demonstrate  that  the zinc  finger region of 
the  ER is neither necessary nor sufficient for the  ER  to  bind 
hsp90. Other work has also suggested that hsp90 may be 
bound  to a region of the  ligand-binding  domain  rather  than 
the  DNA-binding  domain (34). Such a positioning would be 
consistent  with  these  analyses  indicating  an available epitope 
distant  from  the  hsp90-binding  site. 
Using  the gel shift  assay, we detected  no  nuclear  receptor- 
VRE-antibody  ternary complex and only  a small  amount of 
cytosol receptor-VRE-antibody  ternary complex. The nuclear 
dimeric ER  appears  to complex  with the  VRE in such a way 
that  both zinc finger  motifs (CI  and  CII)  are inaccessible to 
the antibodies. Analyses with the ER 8 S cytosol receptor 
complex was  detected  only  with  the  CII finger antiserum A- 
1554, which indicates  that  the  CI finger antibody  can  not  bind 
the  ER  in  the  presence of VRE; however, the  CII finger is 
partially  available  to  bind  the  antibody.  It is conceivable that 
some of the cytosol receptor  binds  the  VRE  as a  monomer, 
for 20 min. Some samples were then incubated with VRE at room 
temperature for 20 min before incubation at 0 “C for 20 h with PBS, 
A-1542 or A-1554, or H222. Samples were centrifuged on 5-30% 
sucrose density gradients in TAE buffer for 15 h at 130,000 X g. [“C] 
Ovalbumin (OV) and [“C]~-globulin (yG) were  used as internal 
markers; ER was incubated with the following reactants in the order 
listed. A: VRE + PBS (0); VRE + H222 (0). B, A-1542 (A); A-1554 
(A); VRE + A-1542 (0); VRE + A-1554 (0). 
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exposing the  CII finger epitope.  In  contrast,  as  the  ER  dimer, 
both  CI  and  CII of the  ER  monomers  interact  and  make  the 
epitope unavailable to  bind  the  antibodies. NMR analyses of 
ER  and  GR have  shown that  the  CI finger is  inserted  in  the 
major groove of the  DNA where it  contacts  bases  important 
for  sequence  recognition (8, 14), and  thus would not be avail- 
able for antibody binding. The  CII finger region extends away 
from the DNA, and  thus  may  be more  accessible for  antibody 
binding when ER is  bound  to VRE. Our  results  are  consistent 
with  the  NMR  analyses (8) using  native  ER. 
Steric hindrance by VRE interaction appears to prevent 
binding of the  DNA  domain  antibodies.  It would appear  that 
ER has a higher affinity for VRE than for the antiserum, 
allowing the  VRE  to displace the  antibody from these  epitopes 
on  the  ER.  Even  when  antibody  binding precedes VRE  bind- 
ing, the receptor’s high affinity for VRE, K d  -0.3 nM (20), 
does not allow antibody binding. These  are  among  the  first 
studies to evaluate the structural binding interactions of 
different forms of the native mouse uterine  ER  to specific 
estrogen-responsive DNA sequences. Our findings using a 
short response element  sequence  indicate  the  DNA-binding 
domain is accessible in different ER forms,  and hsp90 or  other 
factors  do  not  appear  to be blocking this  domain of the  ER. 
Cytosol ER does not  appear to require  any  structural  change 
such  as  activation  in  order  for  the  two zinc  finger motifs  in 
the  DNA-binding  domain  to  be accessible  for DNA  interac- 
tions.  These  structural  properties  are  somewhat  unique  to  the 
ER, since cytosol progesterone receptor has been shown to 
require dissociation of hsp proteins in order to bind DNA 
(35). 
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